JPWO2022000091A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022000091A5 JPWO2022000091A5 JP2022580938A JP2022580938A JPWO2022000091A5 JP WO2022000091 A5 JPWO2022000091 A5 JP WO2022000091A5 JP 2022580938 A JP2022580938 A JP 2022580938A JP 2022580938 A JP2022580938 A JP 2022580938A JP WO2022000091 A5 JPWO2022000091 A5 JP WO2022000091A5
- Authority
- JP
- Japan
- Prior art keywords
- linear
- compound according
- alkyl
- branched
- co2h
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025094025A JP2025143280A (ja) | 2020-06-30 | 2025-06-05 | トリプタミンプロドラッグ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063045901P | 2020-06-30 | 2020-06-30 | |
| US63/045,901 | 2020-06-30 | ||
| US202063109095P | 2020-11-03 | 2020-11-03 | |
| US63/109,095 | 2020-11-03 | ||
| US17/364,047 US11292765B2 (en) | 2020-06-30 | 2021-06-30 | Tryptamine prodrugs |
| US17/364,047 | 2021-06-30 | ||
| PCT/CA2021/050907 WO2022000091A1 (en) | 2020-06-30 | 2021-06-30 | Tryptamine prodrugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025094025A Division JP2025143280A (ja) | 2020-06-30 | 2025-06-05 | トリプタミンプロドラッグ |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023531311A JP2023531311A (ja) | 2023-07-21 |
| JP2023531311A5 JP2023531311A5 (https=) | 2024-07-09 |
| JPWO2022000091A5 true JPWO2022000091A5 (https=) | 2024-07-09 |
| JP7702654B2 JP7702654B2 (ja) | 2025-07-04 |
Family
ID=79032374
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580938A Active JP7702654B2 (ja) | 2020-06-30 | 2021-06-30 | トリプタミンプロドラッグ |
| JP2025094025A Pending JP2025143280A (ja) | 2020-06-30 | 2025-06-05 | トリプタミンプロドラッグ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025094025A Pending JP2025143280A (ja) | 2020-06-30 | 2025-06-05 | トリプタミンプロドラッグ |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11292765B2 (https=) |
| EP (1) | EP4172145A4 (https=) |
| JP (2) | JP7702654B2 (https=) |
| KR (2) | KR20250103811A (https=) |
| CN (3) | CN115867533B (https=) |
| AU (1) | AU2021302692A1 (https=) |
| CA (1) | CA3181092A1 (https=) |
| IL (2) | IL299506B2 (https=) |
| MX (1) | MX2022016212A (https=) |
| WO (1) | WO2022000091A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114787363A (zh) | 2019-10-01 | 2022-07-22 | 恩派瑞安神经科学公司 | 对真菌进行遗传工程化以调节色胺表达 |
| MX2022009528A (es) | 2020-02-04 | 2022-11-14 | Mindset Pharma Inc | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| AU2021268204A1 (en) | 2020-05-08 | 2022-12-08 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| CN115867533B (zh) * | 2020-06-30 | 2024-07-23 | 加拿大瑞安神经科学公司 | 色胺前药 |
| WO2022040802A1 (en) * | 2020-08-26 | 2022-03-03 | Magicmed Industries Inc. | Glycosylated psilocybin derivatives and methods of using |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| EP4263504A4 (en) * | 2020-12-18 | 2025-05-14 | COMPASS Pathfinder Limited | Modified indole alkaloids for therapeutic uses |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| EP4126857A1 (en) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Ergoline analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| BR112023025599A2 (pt) | 2021-06-08 | 2024-02-20 | Entheogenix Biosciences Inc | Ativadores de dimetoxifenilalquilamina de receptores de serotonina. |
| CA3225133A1 (en) | 2021-07-07 | 2023-01-12 | Matthew Alexander James Duncton | N,n-dimethyltryptamine and related psychedlics and uses thereof |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| WO2023023347A1 (en) * | 2021-08-20 | 2023-02-23 | Terran Biosciences Inc. | Prodrugs and derivatives of psilocin and uses thereof |
| EP4429672A4 (en) | 2021-11-12 | 2025-04-30 | Terran Biosciences Inc. | PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID FORMS THEREOF |
| US12404238B2 (en) | 2021-12-10 | 2025-09-02 | Caamtech, Inc. | Psilocybin derivatives |
| JP2024546138A (ja) * | 2021-12-14 | 2024-12-17 | レユニオン ニューロサイエンス，インコーポレイテッド | トリプタミンプロドラッグ |
| EP4457203A4 (en) | 2021-12-27 | 2025-12-17 | Atai Therapeutics Inc | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS |
| JP2024545787A (ja) | 2021-12-30 | 2024-12-11 | アタイ セラピューティクス， インコーポレイテッド | 一酸化窒素送達剤としてのジメチルトリプタミン類似体 |
| EP4457336A4 (en) | 2021-12-31 | 2026-01-14 | Empyrean Neuroscience Inc | ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS |
| WO2023133477A1 (en) * | 2022-01-06 | 2023-07-13 | Terran Biosciences, Inc. | Salts and solid forms of 4-hydroxy-n,n-diisopropyltryptamine hemi-glutarate and hemi-succinate |
| WO2023147423A1 (en) * | 2022-01-28 | 2023-08-03 | Miralogx Llc | Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US20250186369A1 (en) * | 2022-03-07 | 2025-06-12 | Drexel University | Compounds, compositions, and methods for treating, ameliorating, and/or prventing cocaine use disorder |
| US12065404B2 (en) | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| EP4493542A4 (en) * | 2022-03-18 | 2026-03-04 | Enveric Biosciences Canada Inc | C4-CARBONOTHIOATE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USE |
| AU2022446955A1 (en) * | 2022-03-18 | 2024-11-07 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| EP4493544A4 (en) * | 2022-03-18 | 2026-03-04 | Enveric Biosciences Canada Inc | TRYPTAMINE DERIVATIVE SALTS SUBSTITUTED WITH C4-CARBOXYLIC ACID AND C4-CARBONOTHIOATE AND METHODS OF USE |
| WO2023201293A2 (en) * | 2022-04-13 | 2023-10-19 | Caamtech, Inc. | Tryptamine derivatives |
| CN115521240B (zh) * | 2022-06-01 | 2024-05-28 | 杭州奥泰生物技术股份有限公司 | 一种二甲基色胺半抗原和人工抗原及其制备方法与应用 |
| EP4561527A2 (en) * | 2022-07-27 | 2025-06-04 | Reconnect Labs AG | Highly soluble formulations of harmine |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| CN116283885B (zh) * | 2022-12-01 | 2025-02-14 | 杭州奥泰生物技术股份有限公司 | 一种帕罗西汀半抗原和人工抗原及其制备方法与应用 |
| JP2026501775A (ja) * | 2023-01-05 | 2026-01-16 | リユニオン・ニューロサイエンス、インコーポレイテッド | トリプタミンプロドラッグの薬物動態の改善 |
| WO2024178051A2 (en) * | 2023-02-22 | 2024-08-29 | Caamtech, Inc. | Tryptamine derivatives |
| EP4704822A1 (en) | 2023-05-01 | 2026-03-11 | ATAI Therapeutics, Inc. | Compositions and methods for treatment of diseases and disorders |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2025099725A1 (en) * | 2023-11-09 | 2025-05-15 | Hadasit Medical Research Services And Development Ltd. | Conjugates and uses thereof |
| WO2025238416A1 (en) * | 2024-05-16 | 2025-11-20 | Mindset Pharma Inc. | Indole derivatives, uses and compositions thereof |
| WO2025250900A1 (en) * | 2024-05-30 | 2025-12-04 | Caamtech, Inc. | 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate |
| WO2026024591A1 (en) * | 2024-07-22 | 2026-01-29 | Reunion Neuroscience, Inc. | Tryptamine prodrug solid forms |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3075992A (en) * | 1958-09-12 | 1963-01-29 | Sandoz Ltd | Esters of indoles |
| NL243249A (https=) | 1958-09-12 | |||
| CH373381A (de) | 1959-07-13 | 1963-11-30 | Sandoz Ag | Verfahren zur Herstellung neuer basischer Indol-Derivate |
| CH386422A (de) | 1960-03-30 | 1965-01-15 | Sandoz Ag | Verfahren zur Herstellung neuer Ester der Indol-Reihe |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| CA2147991A1 (en) * | 1993-09-01 | 1995-03-09 | Richard A. Glennon | Tryptamine analogs with 5-ht1d selectivity |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| AU2005300045A1 (en) * | 2004-09-27 | 2006-05-04 | Organix, Inc. | Indole compounds useful as serotonin selective agents |
| PL2352497T3 (pl) | 2008-10-31 | 2017-08-31 | University Of Mississippi | Proces przygotowania estrów aminokwasowych delta-9-thc |
| US20180021326A1 (en) | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| EP4219498A1 (en) * | 2019-03-07 | 2023-08-02 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations |
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| CN115867533B (zh) * | 2020-06-30 | 2024-07-23 | 加拿大瑞安神经科学公司 | 色胺前药 |
| EP4263504A4 (en) * | 2020-12-18 | 2025-05-14 | COMPASS Pathfinder Limited | Modified indole alkaloids for therapeutic uses |
-
2021
- 2021-06-30 CN CN202180046999.1A patent/CN115867533B/zh active Active
- 2021-06-30 CN CN202410898893.XA patent/CN119285526A/zh active Pending
- 2021-06-30 CN CN202410898937.9A patent/CN119285527A/zh active Pending
- 2021-06-30 KR KR1020257021837A patent/KR20250103811A/ko active Pending
- 2021-06-30 EP EP21832431.7A patent/EP4172145A4/en active Pending
- 2021-06-30 AU AU2021302692A patent/AU2021302692A1/en active Pending
- 2021-06-30 KR KR1020237003292A patent/KR102829078B1/ko active Active
- 2021-06-30 US US17/364,047 patent/US11292765B2/en active Active
- 2021-06-30 MX MX2022016212A patent/MX2022016212A/es unknown
- 2021-06-30 IL IL299506A patent/IL299506B2/en unknown
- 2021-06-30 JP JP2022580938A patent/JP7702654B2/ja active Active
- 2021-06-30 WO PCT/CA2021/050907 patent/WO2022000091A1/en not_active Ceased
- 2021-06-30 CA CA3181092A patent/CA3181092A1/en active Pending
-
2022
- 2022-02-24 US US17/679,439 patent/US20220177427A1/en not_active Abandoned
-
2024
- 2024-09-30 US US18/902,773 patent/US20250129023A1/en active Pending
-
2025
- 2025-04-30 IL IL320601A patent/IL320601A/en unknown
- 2025-06-05 JP JP2025094025A patent/JP2025143280A/ja active Pending
- 2025-08-22 US US19/308,120 patent/US20250382267A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022000091A5 (https=) | ||
| IL303288A (en) | N,N-Dimethyltryptamine compounds partially or fully deuterated | |
| NZ516298A (en) | Process for the preparation of pure citalopram (5-cyano-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)phthalane) by reacting 5-substituted-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)phthalane with a cyanide source, then treating the crude citalopram product with an amide or an amide-like group | |
| JP2005530722A5 (https=) | ||
| JP2006524222A5 (https=) | ||
| RU2005109913A (ru) | Азабициклоалкильные эфиры и их применение в качестве агонистов альфа7-nachr | |
| GB0315966D0 (en) | Compounds | |
| KR890006602A (ko) | 항균제로서 유용한 아미노메틸 옥소옥사졸리디닐 아로인벤젠 유도체 | |
| CH616080A5 (https=) | ||
| KR930702334A (ko) | 5 하이드록시트립타민 수용체 길항제로서의 인돌우레아 | |
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JP2017533964A5 (https=) | ||
| JP2020111571A5 (https=) | ||
| JPWO2020118060A5 (https=) | ||
| JP2019537624A5 (https=) | ||
| JP2005512965A5 (https=) | ||
| JP2002529497A5 (https=) | ||
| SE7513391L (sv) | Sett att framstella salter av piperidyl-indolderivat | |
| KR890006228A (ko) | 항종양제로서 폴리아민 유도체 | |
| DE69909782D1 (de) | Verwendung von benzofuroxanderivaten zur behandlung von angina pectoris | |
| JPWO2020232274A5 (https=) | ||
| JPWO2023108260A5 (https=) | ||
| KR910004598A (ko) | 2,3-디하이드로-1-(피리디닐아미노)-인돌, 이의 제조방법 및 약제로서 이의 용도 | |
| RU2005138143A (ru) | Митилиндолы и метилпирролопиридины в качестве l-1-адренергических агонистов | |
| JP2009508952A5 (https=) |